GlassScriptPhysician profile
Lisa Ann Mueller
NPI 1063583383
$25,471.14
in general payments reported to CMS, 2019-2025
24 companies · $3,031 in 2025
The $3,031 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85.23 · 2020: $52.65 · 2021: $180 · 2022: $6,844 · 2023: $4,957 · 2024: $10K · 2025: $3,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,670 · Food and Beverage: $4,920 · Travel and Lodging: $4,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,670.00 |
| Food and Beverage | $4,920.42 |
| Travel and Lodging | $4,719.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $15,585.20 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $3,164.77 | 2023-2024 | Zinplava, Dificid |
| Abbvie INC. | $1,958.26 | 2020-2025 | |
| Genentech, INC. | $1,434.07 | 2025 | |
| Celgene Corporation | $681.87 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $578.95 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $555.24 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $453.35 | 2022-2025 | Tremfya, Stelara, Remicade |
| Lilly USA, LLC | $187.96 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $166.80 | 2023-2025 | Ocaliva |
| Ardelyx, INC. | $136.00 | 2023-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $135.14 | 2024 | Iqirvo, Bylvay |
| Fujifilm Healthcare Americas Corporation | $85.82 | 2024 | |
| Ferring Pharmaceuticals INC. | $72.89 | 2019-2023 | Rebyota |
| Braintree Laboratories, INC. | $71.52 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $58.34 | 2023-2025 | |
| Genzyme Corporation | $26.39 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $26.18 | 2022 | |
| Novo Nordisk INC | $25.38 | 2025 | Wegovy |
| Qol Medical, LLC | $24.74 | 2025 | Sucraid |
| Ironwood Pharmaceuticals, INC | $23.10 | 2024 | |
| Orphalan INC | $19.17 | 2025 | Cuvrior |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Mueller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.